# Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

> **NCT00651326** · PHASE3 · TERMINATED · sponsor: **NCIC Clinical Trials Group** · enrollment: 48 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** bicalutamide
- **DRUG:** buserelin
- **DRUG:** flutamide
- **DRUG:** goserelin
- **DRUG:** leuprolide acetate
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** quality-of-life assessment
- **RADIATION:** radiation therapy
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00651326
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06-02
- **Primary completion:** 2010-05-14
- **Final completion:** 2011-01-18
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651326, "Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00651326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*